New combo therapy aims to improve survival in early-spread prostate cancer
NCT ID NCT07237269
First seen Nov 19, 2025 · Last updated May 25, 2026 · Updated 26 times
Summary
This study is for men with prostate cancer that has spread to pelvic lymph nodes visible only on a special PET scan. It compares standard hormone therapy plus radiation to a stronger combination that includes abiraterone and prednisone. The goal is to see if the stronger treatment helps men live longer without the cancer getting worse. About 140 participants will be followed for 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68198, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.